PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: 68Ga-FAPI-JNU.
- Who it may be relevant to
- Registry conditions: Cancer, Solid Malignancies. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To investigate the biological distribution of a new tracer 68Ga-FAPI-JNU in the primary, metastatic and normal tissues of patients with malignant tumors, and to evaluate the biological distribution of 68GA-FAPI-JNU with standardized uptake values.
Detailed description
PET/CT imaging was performed about 1 hour after the patient was injected with the novel tracer 68Ga-FAPI-JNU. SUVmax and SUVmean values of the area of interest were mapped by two diagnostic physicians with more than 5 years of experience after the imaging was completed.
Interventions
- Drug 68Ga-FAPI-JNU
Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person
Primary outcome measures
- Evaluation of the distribution of 68Ga-FAPI-JNU in tumors, metastases and normal tissues [Time frame: 4 hour]
Eligibility criteria
Inclusion criteria
- The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;
- Age 18-85 years old, male or female;
- Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI;
- ECOG score is 0-3 points;
Exclusion criteria
- Patients with a history or allergic constitution to any component of the developer, including alcohol;
- pregnant or lactating women;
- Patients with mental illness or related history;
- Patients who cannot or cannot undergo a PET/CT scan;
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
China · 1 center
- Affiated Hospital of Jiangnan University — Wuxi
Identifiers
NCT: NCT06684028 · LS2024013